Effect of RO7049665 on the Time to Relapse Following Steroid Tapering in Participants With Autoimmune Hepatitis (AIH)
Study Details
Study Description
Brief Summary
The primary objective of the study is to evaluate the effect of RO7049665 on time to relapse following forced corticosteroid (CCS) tapering as measured by the hazard ratio between RO7049665 7.5 milligrams (mg) and placebo arm.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: RO7049665 3.5 mg Participants will receive RO7049665 3.5 mg, administered as subcutaneous (SC) injection, every 2 weeks (Q2W) until participants experience relapse or the study is closed. |
Drug: RO7049665
RO7049665, subcutaneous injection, Q2W.
|
| Experimental: RO7049665 7.5 mg Participants will receive RO7049665 7.5 mg, administered as SC injection, Q2W until participants experience relapse or the study is closed. |
Drug: RO7049665
RO7049665, subcutaneous injection, Q2W.
|
| Placebo Comparator: Placebo Participants will receive RO7049665-matching placebo, administered as SC injection, Q2W until participants experience relapse or the study is closed. |
Other: Placebo
RO7049665-matching placebo, subcutaneous injection, Q2W.
|
Outcome Measures
Primary Outcome Measures
- Time to Relapse for RO7049665 7.5 mg Versus Placebo [From randomization (Day 1) up to relapse or end of the study (up to approximately 25 months)]
Secondary Outcome Measures
- Change from Baseline in Alanine Aminotransferase (ALT) [Up to end of the study (up to approximately 25 months)]
- Change from Baseline in Aspartate Aminotransferase (AST) [Up to end of the study (up to approximately 25 months)]
- Change from Baseline in Immunoglobulin G (IgG) [Up to end of the study (up to approximately 25 months)]
- Time to Relapse for RO7049665 3.5 mg Versus Placebo [From Randomization (Day 1) up to relapse or end of the study (up to approximately 25 months)]
- Percentage of Participants with Adverse Events (AEs) [Up to end of the study (up to approximately 25 months)]
- Number of Participants with Anti-drug Antibody (ADA) Emergence and Neutralizing Potential [Up to end of the study (up to approximately 25 months)]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Participants with a definite diagnosis of AIH (type 1, 2 and 3) as per simplified or revised original diagnostic criteria
-
Participants who have been in biochemical remission for > 2 years (or less if according to the local practice) prior to randomization
-
Participants who have been on stable treatment (corticosteroids [CCSs] +/- non-specific immunosuppressants [NSIs]) for at least 3 months prior to randomization and who have not had a dose increase in the previous 6 months prior to randomization
-
No signs of liver inflammation on a liver biopsy taken no more than 12 months prior to randomization
-
Participants with AIH who have previously not attempted (or not attempted in the last 3 years, if this is the local practice) to taper CCSs to 0 mg/day
-
Body mass index within the range of 18-35 kilograms per meter square (kg/m^2)
-
Women of childbearing potential who agree to remain abstinent or use at least one acceptable contraceptive method during the treatment period and for at least 28 days after the final dose of study drug
Exclusion Criteria:
-
Participants with cirrhosis (F4 fibrosis by Fibroscan®) with significant impairment of liver function (Child Pugh category B or C)
-
Any other autoimmune disease requiring immunomodulating treatment
-
History of infection with hepatitis B, human immunodeficiency virus, active hepatitis C virus (HCV) infection, detection of replicating cytomegalovirus (CMV) or Epstein-Barr virus (EBV)
-
Active infections requiring systemic therapy with antibiotic, antiviral, or antifungal treatment or febrile illness within 7 days before Day-1
-
History of primary or acquired immunodeficiency
-
Pregnant or lactating female participants
-
Symptomatic herpes zoster within 3 months prior to screening
-
History of active or latent tuberculosis or a positive Quantiferon Gold test
-
History of clinically significant severe drug allergies, multiple drug allergies, allergy to any constituent of the product, or intolerance to topical steroids
-
Lymphoma, leukemia, or any malignancy within the past 5 years, except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years and in situ carcinoma of the cervix that was completely removed surgically. Breast cancer within the past 10 years
-
Significant uncontrolled comorbidity, such as cardiac, pulmonary, renal, hepatic, endocrine, or gastrointestinal disorders
-
Any condition or disease detected during the medical interview/physical examination that would render the participant unsuitable for the study, place the participant at undue risk, or interfere with the ability of the participant to complete the study in the opinion of the Investigator
-
CCSs of <5 mg/day, or <2.5 mg CCSs plus immune suppressant, or <3 mg/day budesonide with or without immune suppressant
-
CCSs >20 mg/day or >9 mg/day budesonide
-
Non-specific immunosuppressant (NSI) daily dose higher than recommended standard of care therapy
-
T or B cell-depleting therapy within the last 12 months or T- or B-cell number below normal due to depleting therapy
-
Leukocyte apheresis within 12 weeks of screening
-
Donation of blood or blood products in excess of 500 milliliters (mL) within 3 months prior to screening.
-
Exposure to any investigational treatment within 6 months prior to Day 1
-
Abnormal hematologic, hepatic enzyme, hepatic function, or biochemistry values
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | The Alfred Hospital - Professor Stuart Roberts' Clinic - The Alfred Centre Location | Melbourne | Victoria | Australia | 3004 |
| 2 | Universite de Montreal - Centre Hospitalier de l'Universite de Montreal CHUM - Hopital Saint-Luc | Montreal | Quebec | Canada | H2X 0A9 |
| 3 | Martin Zeitz Centrum für Seltene Erkrankungen ZSE Hamburg | Hamburg | Germany | 20246 | |
| 4 | Ospedale San Gerardo | Monza | Lombardia | Italy | 20900 |
| 5 | IRCCS Saverio De Bellis; Anatomia Patologica | Castellana Grotte | Puglia | Italy | 70013 |
| 6 | Pusan National University Hospital; division of pulmonology | Busan | Korea, Republic of | ||
| 7 | Korea University Ansan Hospital | Gyeonggi-do | Korea, Republic of | 15355 | |
| 8 | University of Ulsan College of Medicine - Asan Medical Center (AMC) - Asan Liver Center | Seoul | Korea, Republic of | KOR | |
| 9 | Amsterdam UMC - location AMC | Amstermdam | Netherlands | 1105 AZ | |
| 10 | Radboud Universiteit - Radboud Universitair Medisch Centrum Radboudumc | Nijmegen | Netherlands | 6525 GA | |
| 11 | Centro Hospitalar de Vila Real | Vila Real | Portugal | 5000-508 | |
| 12 | King College Hospital NHS Foundation Trust | London | United Kingdom | SE5 9RS | |
| 13 | Nottingham University Hospitals NHS Trust - City Hospital | Nottingham | United Kingdom | NG5 1PB |
Sponsors and Collaborators
- Hoffmann-La Roche
Investigators
- Study Director: Clinical Trials, Hoffmann-La Roche
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- BP42698
- 2020-003990-23